Key result
RAAS inhibitors are linked to ~55% lower ESRD risk in malignant hypertension-associated TMA.
Why the study?
Factors influencing long-term renal outcomes in dialysis-independent patients with biopsy-proven malignant hypertension-associated renal thrombotic microangiopathy remained to be identified.
Does RAAS inhibitor use reduce the risk of progression to end-stage renal disease in patients with malignant hypertension-associated renal thrombotic microangiopathy?
Cohort (n=170)
Does RAAS inhibitor use reduce the risk of progression to end-stage renal disease in patients with malignant hypertension-associated renal thrombotic microangiopathy?
Hazard Ratio: 0.45 (95% CI 0.25–0.82)
p-value: p=0.009
In patients with malignant hypertension-associated renal thrombotic microangiopathy, RAAS inhibitor use is associated with a reduced risk of progression to end-stage renal disease.
No takes yet. Share an insight, caveat, or question.
Higher cholesterol and proteinuria were associated with ESRD progression in MHT-TMA; hypothesis-generating and requires prospective validation before informing care.
Li et al. (2026) conducted a cohort in Malignant hypertension-associated renal thrombotic microangiopathy (n=170). RAAS inhibitor use vs. No RAAS inhibitor use was evaluated on End-stage renal disease (ESRD) (HR 0.45, 95% CI 0.25-0.82, p=0.009). RAAS inhibitor use was associated with a significantly reduced risk of end-stage renal disease (HR 0.45; 95% CI 0.25-0.82; p=0.009) in patients with MHT-associated TMA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: